GfK launches snapshot doc surveys

Share this article:

GfK launched a new product—Flashpoints—allowing marketers to survey 100 physicians in one week. 


The offering will provide a snapshot of physician behaviors or perceptions as they react to a market event or drug launch, for example. The customized survey allows for five close-ended questions, with the option of using open-ended questions for an additional charge, according to a GfK statement. "In circumstances where clients only require a topline market pulse on a given issue-of-the-moment—or when a decision needs to be made imminently—FlashPoints serves as an efficient way to gather reliable, representative and rapid feedback, said Maureen McLaughlin, chief marketing officer at GfK Healthcare, in the statement.


GfK is billing the service as the only one of its kind available. A spokesperson for IMS Health said IMS doesn't offer a comparable one-week survey, but can provide survey results for over 3,000 physicians on a quarterly basis for clients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?